It is known that pasireotide treatment can lead to hyperglycaemia and impaired insulin secretion; hence, when observing cardiac abnormalities in patients undergoing pasireotide treatment, the causative factor may predominantly be diabetes rather than acromegaly. The gene discussed is INS; the disease is diabetes mellitus.